Nuclear Medicine and Biology
Volume 33, Issue 6 , Pages 735-741, August 2006

Comparison of the uptake of [123/125I]-2-iodo-d-tyrosine and [123/125I]-2-iodo-l-tyrosine in R1M rhabdomyosarcoma cells in vitro and in R1M tumor-bearing Wag/Rij rats in vivo

  • Matthias Bauwens

      Affiliations

    • Radiopharmaceutical Chemistry, BEFY, Vrije Universiteit Brussel, 1090 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 2 477 48 60; fax: +32 2 477 48 55.
  • ,
  • Tony Lahoutte

      Affiliations

    • In Vivo Cellular Imaging Center (ICMIC), Vrije Universiteit Brussel, 1090 Brussels, Belgium
  • ,
  • Ken Kersemans

      Affiliations

    • Radiopharmaceutical Chemistry, BEFY, Vrije Universiteit Brussel, 1090 Brussels, Belgium
  • ,
  • Carol Gallez

      Affiliations

    • In Vivo Cellular Imaging Center (ICMIC), Vrije Universiteit Brussel, 1090 Brussels, Belgium
  • ,
  • Axel Bossuyt

      Affiliations

    • In Vivo Cellular Imaging Center (ICMIC), Vrije Universiteit Brussel, 1090 Brussels, Belgium
  • ,
  • John Mertens

      Affiliations

    • Radiopharmaceutical Chemistry, BEFY, Vrije Universiteit Brussel, 1090 Brussels, Belgium

Received 20 March 2006; received in revised form 3 May 2006; accepted 8 May 2006. published online 20 July 2006.

Abstract 

Introduction

Recently, promising results concerning uptake in vivo in tumors of d-amino acids have been published. Therefore, we decided to evaluate the tumor uptake of the d-analogue of [123I]-2-iodo-l-tyrosine, a tracer recently introduced by our group into clinical trials. The uptake of 2-amino-3-(4-hydroxy-2-[123/125I]iodophenyl)-d-propanoic acid (2-iodo-d-tyrosine) was studied in vitro in LAT1-expressing R1M rat rhabdomyosarcoma cells and in vivo in R1M tumor-bearing Wag/Rij rats.

Methods

The uptake of [125I]-2-iodo-l-tyrosine and [125I]-2-iodo-d-tyrosine into R1M cells was determined in appropriate buffers, allowing the study of the involved transport systems. In vivo, the biodistribution in R1M-bearing rats of [123I]-2-iodo-l-tyrosine and [123I]-2-iodo-d-tyrosine was performed by both dynamic and static planar imaging with a gamma camera.

Results

In in vitro conditions, the uptake of both [125I]-2-iodo-l-tyrosine and [125I]-2-iodo-d-tyrosine in the HEPES buffer was 25% higher in the presence of Na+ ions. In the absence of Na+ ions, [125I]-2-iodo-d-tyrosine was taken up reversibly in the R1M cells, with an apparent accumulation, probably for the larger part by the LAT1 system. Dynamic planar imaging showed that the uptake in the tumors of [123I]-2-iodo-d-tyrosine was somewhat lower than that of [123I]-2-iodo-l-tyrosine. At 30 min postinjection, the mean differential uptake ratio values of the l- and d-enantiomers are 2.5±0.7 and 1.7±0.6, respectively. Although the uptake of the d-isomer is lower, probably due to a faster clearance from the blood, the tumor–background ratio is the same as that of the l-analogue.

Conclusion

A large part (75%) of [125I]-2-iodo-d-tyrosine in vitro and [123I]-2-iodo-d-tyrosine in vivo is reversibly highly taken up in R1M tumor cells by Na+-independent LAT transport systems, more likely by the LAT1. The clearance from the blood of [123I]-2-iodo-d-tyrosine in the rats is faster than that of the l-analogue, resulting in a slightly lower tumor uptake but with the same tumor–background ratio.

Keywords: [123/125I]-2-I-d-tyrosine, Amino acid, SPECT, Tumor

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The first author is currently working on his PhD degree.

PII: S0969-8051(06)00092-8

doi:10.1016/j.nucmedbio.2006.05.004

Nuclear Medicine and Biology
Volume 33, Issue 6 , Pages 735-741, August 2006